Hem › Multipelt myelom › New Mexico
Kliniska studier för Multipelt myelom i New Mexico
5 studier för Multipelt myelom söker deltagare vid platser i New Mexico.
Officiell studietext (engelska)
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Christus St. Vincent Regional Cancer Center, Santa Fe
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT07518186A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Christus St. Vincent Regional Cancer Center, Santa Fe
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05552222TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- The University of New Mexico Comprehensive Cancer Center, Albuquerque
- och 2 fler
RekryterarFas 2
Ålder 12 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT02693535A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Farmington
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 aug. 2026 · NCT07227311Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- och 1 fler
RekryterarFas 3
Alla åldrar · Alla kön · Uppdaterad 10 juni 2026 · NCT05561387Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.